Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 93 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

Center for Patient Safety - P0011
    PSO Alternate Legal Name: Missouri Center for Patient Safety
Effective Date and Time of Initial Listing: November 5, 2008 12:01 AM ET
PSO Mailing Address: PO Box 410431, St. Louis, MO 63141
PSO Phone Number: 573-636-1014
Point of Contact: Alexandra Christgen
Point of Contact Phone: 573-636-1014, ext. 1225
Point of Contact Email: achristgen@centerforpatientsafety.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/05/2020 through 11/04/2022
Disclosures & Finding: None
Collaborative Healthcare Patient Safety Organization - P0002
Component of Parent Org(s):
  • California Association of Hospitals and Health Systems (CAHHS)
  • Hospital Quality Institute (HQI)
Effective Date and Time of Initial Listing: November 5, 2008 12:01 AM ET
PSO Mailing Address: 1215 K Street, Suite 800, Sacramento, CA 95814
PSO Phone Number: (916) 552-2600
Point of Contact: Barbara Pon PhD, MS, RN
Point of Contact Phone: (916) 552-7614
Point of Contact Email: bpon@chpso.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/05/2020 through 11/04/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
ECRI and the Institute for Safe Medication Practices PSO - P0008
Component of Parent Org(s):
  • Emergency Care Research Institute d/b/a ECRI
    • Parent Organization Alternate Legal Name: ECRI
Effective Date and Time of Initial Listing: November 5, 2008 12:01 AM ET
PSO Mailing Address: 5200 Butler Pike, Plymouth Meeting, PA 19462
PSO Phone Number: 866-247-3004
Point of Contact: Sheila Rossi MHA
Point of Contact Phone: 610-825-6000, ext. 5281
Point of Contact Email: srossi@ecri.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/05/2020 through 11/04/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
The Quality Center Patient Safety Organization - P0025
Component of Parent Org(s):
  • NCHA, Inc. DBA North Carolina Healthcare Association
  • North Carolina Hospital Foundation, Inc.
Effective Date and Time of Initial Listing: December 10, 2008 12:01 AM ET
PSO Mailing Address: 2400 Weston Parkway, Cary, NC 27513
PSO Phone Number: (919) 677-4212
Point of Contact: Shelby Lassiter
Point of Contact Phone: 919-677-4134
Point of Contact Email: slassiter@ncha.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 12/10/2020 through 12/09/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Vizient™ PSO - P0007
Component of Parent Org(s):
  • Vizient Inc
Effective Date and Time of Initial Listing: November 5, 2008 12:01 AM ET
PSO Mailing Address: 155 North Wacker Drive, 40th floor, Chicago, IL 60606
PSO Phone Number: 312-775-4100
Point of Contact: Ellen M. Flynn RN, MBA, JD
Point of Contact Phone: 312-775-4100
Point of Contact Email: Ellen.Flynn@vizientinc.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/05/2020 through 11/04/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No